secwatch.observer — SEC 8-K summary
======================================

Issuer:     ALNYLAM PHARMACEUTICALS, INC. (ALNY)
CIK:        0001178670
Form:       8-K
Filed at:   2022-09-16T23:59:59+00:00
Accession:  0001193125-22-246487
Event type: debt
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 1.02, 2.03, 3.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Alnylam closes $1.035B convertible note offering; repays $762M credit facility
------------------------------------------------------------------------------

- Issued $1.035B aggregate principal of 1.00% Convertible Senior Notes due 2027 (initial $900M plus $135M additional).
- Conversion rate initially 3.4941 shares per $1,000 principal; conversion price ~$286.20/share, a 35% premium over $212 closing.
- Entered capped call transactions with cap price $424/share; cost ~$118.6M to reduce dilution upon conversion.
- Used ~$762M of proceeds to repay and terminate April 2020 credit agreement.
- Notes mature Sept 15, 2027; interest payable semiannually at 1.00%.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1178670/000119312522246487/0001193125-22-246487-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1178670/000119312522246487/d386201d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-246487

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer